Don S. Dizon

Providence

Director of Women's Cancers, Lifespan Cancer Institute and Contributor at Freelance

Flown the coop. Find me on bluesky or threads. Not yet sure which one will win. Peace out.

Articles

The Evolution of the ASCO Educational Book and the Issues Shaping the Future of Oncology

1 week ago | ascopubs.org | Nate Pennell |Don S. Dizon

On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new companion podcast to further shine a spotlight on the issues shaping the future of modern oncology. TRANSCRIPTDr. Nathan Pennell:Hello, I'm Dr. Nate Pennell, welcoming you to the first episode of our new podcast,ASCO Education: By the Book.
Highlighting American Cancer Society‐funded research in CA: A Cancer Journal for Clinicians

Jan 9, 2025 | acsjournals.onlinelibrary.wiley.com | Don S. Dizon |Christina M Annunziata

Since 1946, the American Cancer Society (ACS) has invested more to find the causes and cures of cancer than any other single nongovernmental, not-for-profit organization. Each year, the ACS extends this support to investigators at institutions across the United States as part of its grants program, funding research for high school interns through world-renowned professors, including the ACS Professorship.
Immunotherapy Shows Activity Among Patients With Gynecologic Clear Cell Carcinoma

Jun 3, 2024 | hmpgloballearningnetwork.com | Don S. Dizon

Conference Coverage Don Dizon, MD, Lifespan Cancer Institute, Providence, Rhode Island, shares insights from the phase 2 BrUOG 354 trial evaluating nivolumab with or without ipilimumab among patients with ovarian and extra-renal clear cell carcinomas. According to Dr Dizon and coauthors, nivolumab plus ipilimumab “warrant further evaluation against standard treatment for people with ovarian [clear cell carcinoma], given the historically chemotherapy-resistant nature of the disease.
Dr Dizon on the Future of Precision Medicine in Ovarian Cancer Management

Apr 23, 2024 | onclive.com | Don S. Dizon

Don S. Dizon, MD, FACP, FASCO, director, Pelvic Malignancies Program, director, Hematology-Oncology Outpatient Clinics, Lifespan Cancer Institute; head, Community Outreach and Engagement, Legorreta Cancer Center; director, Medical Oncology, Rhode Island Hospital; professor, medicine, The Warren Alpert Medical School of Brown University, discusses future directions for precision medicine approaches in the management of ovarian cancer.
Dr Dizon on the Prevalence of Sexual Challenges in Patients With Breast Cancer

Mar 26, 2024 | onclive.com | Don S. Dizon

Don S. Dizon, MD, director, Pelvic Malignancies Program, Lifespan Cancer Institute, head, Community Outreach and Engagement, Legorreta Cancer Center, director, Medical Oncology, Rhode Island Hospital, and professor of medicine, The Warren Alpert Medical School of Brown University, underscores the prevalence of challenges pertaining to sexual intimacy in patients with cancer, specifically discussing those with breast cancer.
a cancer patient's remarkable story

Mar 1, 2024 | kevinmd.com | Damane Zehra |Alison Vasa |Don S. Dizon |Allie Poles

A few weeks back, a young male from Afghanistan visited us in the oncology clinic. He was in his late 20s and came with a translator to facilitate his consultation. He was not very fluent in either Urdu or English but could still understand most of it. He seemed very anxious and perplexed in the initial assessment room. I observed him closely and noticed that there was no family member accompanying him, except the translator who had only come to do his part of the job.
Becoming the new editor for CA: The future is now

Jan 27, 2024 | acsjournals.onlinelibrary.wiley.com | Don S. Dizon

CA: A Cancer Journal for Clinicians (CA) was not a journal I ever saw myself publishing in let alone leading; its impact factor and prestige seemed out of reach for me—such is the Imposter Syndrome. Still, I came across the opportunity to become its editor and I applied, thinking I would regret it if I did not at least try. To my delight, I was chosen to succeed Ted Gansler, who had led CA as its editor for 23 years.
Cancer statistics 2024: All hands on deck

Jan 16, 2024 | acsjournals.onlinelibrary.wiley.com | Don S. Dizon |Arif Kamal

The 2024 update to Cancer Statistics from the American Cancer Society estimates that over 2,000,000 people this year will hear the words, “you have cancer.”1 This amounts to nearly 5500 people each day, or the equivalent to one person experiencing this every 15 seconds. This marks the first time incidence has eclipsed 2 million Americans, with more people being diagnosed at earlier stages of these diseases, when cure rates are the highest.
a brain tumor diagnosis

Dec 12, 2023 | kevinmd.com | Emily Schehlein |Thomas L. Amburn |Jimmy Chen |Don S. Dizon

In medicine, the sickest patients always seem to come on Friday afternoons. At the end of the week, I’m hoping to move quickly through my last few patients – a small corneal abrasion, a routine follow-up, or a stable glaucoma exam. I’m prepared for a pleasant conversation and some friendly banter about rival football teams playing Saturday morning. But I’m wary. I have been doing this long enough to know the 4:30 to 5:30 p.m. “witching hour” approaches.
AI's role in streamlining colorectal cancer screening [PODCAST]

Dec 6, 2023 | kevinmd.com | Michael Joyce |Alison Vasa |Martha Rosenberg |Don S. Dizon

Subscribe to The Podcast by KevinMD. Catch up on old episodes!Join Shrujal Baxi, an oncologist passionate about AI, as we delve into how artificial intelligence is revolutionizing colorectal cancer detection while navigating the complexities of prior authorization. Discover how AI streamlines screening, reduces administrative burdens, and enhances patient outcomes in the face of health care policy barriers. Shrujal Baxi is an oncologist.